Sia Charles, Weinem Michael
Department of Immunology, United Biomedical Inc., 25 Davids Drive, Hauppage, New York 11788, USA.
Rev Diabet Stud. 2005 Summer;2(2):97-109. doi: 10.1900/RDS.2005.2.97. Epub 2005 Aug 10.
The use of DNA-based genetic typing has enabled the identification of type 1 diabetes mellitus (T1DM) susceptible and protective major histocompatibility complex (MHC) class II alleles and haplotypes. The application of this approach has also progressed to locate MHC class I alleles that contribute to the clinicopathology of T1DM. Recent studies have shown a widespread involvement of genes from the MHC class I gene region in the clinicopathology of T1DM. These genes are shown to be involved in contributing to progression from the preclinical stage of the disease, which is characterized by the occurrence of islet-specific antibodies, to clinical disease and also to the occurrence of autoimmunity. They can either contribute directly to disease development or indirectly in concert with other susceptible MHC class II alleles or haplotypes via linkage disequilibrium. Class I alleles may also be negatively associated with T1DM. These findings are useful for the development of future strategies in designing tolerogenic approaches for the prevention or even reversal of T1DM. In this article, the latest evidence for the different kinds of participation of HLA class I genes in the etiology of T1DM is reviewed. A meta-analysis which included existing association studies was also carried out in order to re-assess the relevance of class I genes in diabetes development. The analysis of an enlarged heterogeneous sample confirmed the involvement of previously detected serotypes in the etiology of T1DM, such as A24, B8 and B18, and revealed hitherto unknown associations with B60 and B62. The analysis points out that much of the conflicting results of previous association studies originate from inadequate sample sizes and accentuate the value of future investigations of larger samples for identifying linkage in multigenic diseases.
基于DNA的基因分型技术已能够鉴定出1型糖尿病(T1DM)易感和具有保护作用的主要组织相容性复合体(MHC)II类等位基因及单倍型。这种方法的应用也已发展到定位与T1DM临床病理相关的MHC I类等位基因。最近的研究表明,MHC I类基因区域的基因广泛参与T1DM的临床病理过程。这些基因被证明参与了疾病从以胰岛特异性抗体出现为特征的临床前期发展到临床疾病阶段,以及自身免疫的发生过程。它们既可以直接促成疾病发展,也可以通过连锁不平衡与其他易感的MHC II类等位基因或单倍型协同发挥间接作用。I类等位基因也可能与T1DM呈负相关。这些发现对于未来设计诱导免疫耐受方法以预防甚至逆转T1DM的策略发展具有重要意义。在本文中,我们综述了HLA I类基因在T1DM病因学中不同参与方式的最新证据。我们还进行了一项纳入现有关联研究的荟萃分析,以重新评估I类基因在糖尿病发展中的相关性。对扩大后的异质性样本进行分析,证实了先前检测到的血清型如A24、B8和B18参与T1DM的病因学,并揭示了与B60和B62迄今未知的关联。分析指出,先前关联研究中许多相互矛盾的结果源于样本量不足,并强调了未来对更大样本进行研究以确定多基因疾病连锁关系的价值。